Clarivate epidemiology’s coverage of Stargardt disease (STGD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence in each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s STGD forecast will answer the following questions:
How will demographic trends, such as population aging, improving life expectancy, and population migration, affect the epidemiology of STGD over the 20-year forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of diagnosed prevalent cases for each forecast year, Clarivate epidemiology provides at least 10 years of forecast data for the following subpopulations:
Diagnosed incident cases.
Diagnosed incident cases by visual acuity in the worst eye.
Diagnosed prevalent cases by visual acuity in the worst eye.
Literature review (studies included in/excluded from the analyses of Stargardt disease)
Diagnosed incident cases of Stargardt disease
Diagnosed prevalent cases of Stargardt disease
Stargardt disease by visual acuity
Risk / protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviation table
Ullas Ulahannan
Ullas Ulahannan, M.P.H., is an associate epidemiologist at Clarivate. Previously, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.
Surup Dey
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.
